Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cardiovascular progenitor cell-derived extracellular vesicle-enriched secretome
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramyocardial
01
Overview
Cardiovascular progenitor cell-derived extracellular vesicle-enriched secretome (EV-CPC) is an investigational cell-free regenerative therapy developed by Assistance Publique - Hôpitaux de Paris (AP-HP). It consists of the secretome of cardiovascular progenitor cells (CPCs)—which are themselves derived from human embryonic stem cells (hESCs)—specifically enriched for extracellular vesicles (EVs) such as exosomes. The therapy is designed to treat non-ischemic dilated cardiomyopathy (NIDCM) by delivering a complex cargo of bioactive proteins and microRNAs directly to the myocardium. These molecules exert therapeutic effects through paracrine signaling, promoting cardiomyocyte survival, stimulating angiogenesis, and modulating the local inflammatory response to prevent adverse cardiac remodeling. This approach aims to provide the regenerative benefits of stem cell therapy while avoiding the risks associated with cell engraftment, such as tumorigenicity or immune rejection.
- Other names
- EV-enriched secretome of cardiovascular progenitor cellsCPC-EVcardiovascular progenitor cell-derived extracellular vesicles
Beyond the preview
Go deeper on cardiovascular progenitor cell-derived extracellular vesicle-enriched secretome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cardiovascular progenitor cell-derived extracellular vesicle-enriched secretome.